The Journal of Practical Medicine >
A study of underlying mechanisms of artemisinin inhibiting glycolysis through HIF-1α/LDHA pathway to improve pulmonary vascular remodeling
Received date: 2024-07-16
Online published: 2025-01-14
Objective Aimed at investigating the effect and molecular mechanism of artemisinin on hemodynamics and vascular remodeling in monocrotaline（MCT） -induced pulmonary arterial hypertension （PAH） rats. Methods 30 male SD rats were randomly divided into 3 groups （n = 10）： control group， MCT-induced PAH group （MCT group， 60 mg/kg） and artemisinin intervention group （50 mg/kg）. At 28 days after modeling， the right ventricular systolic pressure （RVSP）， mean pulmonary artery pressure （mPAP）， heart rate and right ventricular hypertrophy index （RVHI） were measured to evaluate the development of PAH. HE staining and α-SMA immunohistochemistry were used to observe the morphology and assess muscularization of pulmonary arterioles， and the percentage of medial wall thickness （WT%），the percentage of vascular wall area （WA%） and the proportion of muscular vessels were calculated to evaluate the degree of pulmonary vascular remodeling. The mRNA and protein levels of HIF-1α and LDHA were detected by real-time PCR and Western blot， respectively. Pyruvate and lactate concentration in lung tissue was measured using pyruvate and lactateassay kit. Results Compared with the control group， the RVSP， mPAP， heart rate and RVHI were significantly increased in MCT-induced PAH rats （all P < 0.05）. Histological analysis showed that the increasedmedial wall thickness of small pulmonary arteries and vascular muscularization were observed in MCT-treated rats compared with control rats. WT%， WA% and muscularization degrees of pulmonary arterioles were higher in MCT-treated rats than those in the control group （all P < 0.05）， suggesting successful construction of PAH model. Compared with the MCT group， the RVSP， mPAP， heart rate and RVHI decreased in the rats treated with artemisinin（all P < 0.05）， accompanied with lower WT% and WA% （P < 0.05）， and muscularization of pulmonary arterioles was improved （P < 0.05）. Further study showed the mRNA and protein levels ofHIF-1α and LDHA in lung tissue of MCT-induced PAH rats were higher than those in the control group， the content of lactate and pyruvate and the ratio of lactate to pyruvate were higher than that in the control group （all P < 0.05）. However， the mRNA and protein levels of HIF-1α and LDHA in lung tissue of rats treated with artemisinin were lower than those in the MCT group， the content of lactate and pyruvate and the ratio of lactate to pyruvate were lower than that in the MCT group （all P<0.05）. Conclusion Artemisinin improves hemodynamic and pulmonary vascular remodeling in PAH rats through inhibiting HIF-1α/LDHA signaling pathway-mediated glycolysis.
Wenhua SHI , Yuqian CHEN , Yonghong ZHANG , Cong LI , Cui ZHAI , Ni YANG , Rui KE . A study of underlying mechanisms of artemisinin inhibiting glycolysis through HIF-1α/LDHA pathway to improve pulmonary vascular remodeling[J]. The Journal of Practical Medicine, 2025 , 41(1) : 15 -22 . DOI: 10.3969/j.issn.1006-5725.2025.01.003
| 1 | ROSENKRANZ S. 2022 ESC/ERS guidelines on the diagnostics and treatment of pulmonary hypertension： A focussed review［J］. Herz， 2023，48（1）：23-30. doi:10.1007/s00059-022-05155-1 |
| 2 | SAFAIE Q E， STEWART D J. Cellular senescence in the pathogenesis of pulmonary arterial hypertension： the good， the bad and the uncertain［J］. Front Immunol， 2024， 15： 1403669. doi:10.3389/fimmu.2024.1403669 |
| 3 | POKHAREL M D， MARCIANO D P， FU P， et al. Metabolic reprogramming， oxidative stress， and pulmonary hypertension［J］. Redox Biol， 2023， 64：102797. doi:10.1016/j.redox.2023.102797 |
| 4 | GRIFFITHS K， GRAND R J， HORAN I， et al. Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells［J］.Vascul Pharmacol， 2024， 156： 107399. doi:10.1016/j.vph.2024.107399 |
| 5 | ZHAO S S， LIU J L， WU Q C， et al. Role of histone lactylation interference RNA mA modification and immune microenvironment homeostasis in pulmonary arterial hypertension［J］. Front Cell Dev Biol， 2023， 11： 1268646. doi:10.3389/fcell.2023.1268646 |
| 6 | YEGAMBARAM M， SUN X， LU Q， et al. Mitochondrial hyperfusion induces metabolic remodeling in lung endothelial cells by modifying the activities of electron transport chain complexes I and III［J］. Free Radic Biol Med， 2024， 210：183-194. doi:10.1016/j.freeradbiomed.2023.11.008 |
| 7 | 艾丽菲热·买买提， 高静， 于子翔，等. 肺动脉平滑肌细胞外泌体上调miR-106b-5p增强肺动脉内皮细胞Warburg效应促进动脉型肺动脉高压的分子机制［J］. 实用医学杂志，2023，39（17）：2190-2195. doi:10.3969/j.issn.1006-5725.2023.17.007 |
| 8 | GUAN L， WANG H， XU X， et al. Therapeutical Utilization and Repurposing of Artemisinin and Its Derivatives： A Narrative Review［J］. Adv Biol （Weinh）， 2023， 7（8）：e2300086. doi:10.1002/adbi.202300086 |
| 9 | BAO C， HE Q， WANG H， et al. Artemisinin and Its Derivate Alleviate Pulmonary Hypertension and Vasoconstriction in Rodent Models［J］. Oxid Med Cell Longev， 2022， 2782429. doi:10.1155/2022/2782429 |
| 10 | TANG M， WANG R， FENG P， et al. Dihydroartemisinin attenuates pulmonary hypertension through inhibition of pulmonary vascular remodeling in rats ［J］. J Cardiovasc Pharmacol， 2020， 76（3）：337-348. doi:10.1097/fjc.0000000000000862 |
| 11 | YU H， LIU J， DONG Y， et al. Anti-hypoxic effect of dihydroartemisinin on pulmonary artery endothelial cells. Biochemical and biophysical research communications［J］.Biochem Biophys Res Commun， 2018， 506（4）：840-846. doi:10.1016/j.bbrc.2018.10.176 |
| 12 | GAO Y， GONG Y， LU J， et al.Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma［J］. Biochem Pharmacol， 2024， 225：116294. doi:10.1016/j.bcp.2024.116294 |
| 13 | LIU Q， CHEN X， TAN Y， et al. Natural products as glycolytic inhibitors for cervical cancer treatment： A comprehensive review［J］. Biomed Pharmacother， 2024， 175：116708. doi:10.1016/j.biopha.2024.116708 |
| 14 | ZHANG Y， WANG Y， LI Y， et al. Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer［J］. Biochem Pharmacol， 2022， 198：114941. doi:10.1016/j.bcp.2022.114941 |
| 15 | BAILISTRIERI A， MAKINO A， YUAN J X. Pathophysiology and pathogenic mechanisms of pulmonary hypertension： Role of membrane receptors， ion channels， and Ca2+ signaling［J］. Physiol Rev， 2023， 103（3）：1827-1897. doi:10.1152/physrev.00030.2021 |
| 16 | ZAFEIROPOULOS S， AHMED U， BEKIARIDOU A， et al. Ultrasound ueuromodulation of an anti-inflammatory pathway at the spleen improves experimental pulmonary hypertension［J］. Circ Res， 2024， 135： 41-56. doi:10.1161/circresaha.123.323679 |
| 17 | CHEN C N， HAJJI N， YEH F C， et al. Restoration of Foxp3regulatory T cells by HDAC-dependent epigenetic modulation plays a pivotal role in resolving pulmonary arterial hypertension pathology［J］.Am J Respir Crit Care Med， 2023， 208： 879-895. doi:10.1164/rccm.202301-0181oc |
| 18 | 张波涛，王雅蓉，张婷，等. 甜菜碱调控RhoA/ROCK抑制野百合碱致大鼠肺动脉高压［J］. 实用医学杂志，2023，39（15）：1876-1880. |
| 19 | WANG J， LIU C， HUANG S， et al. Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension［J］. Eur J Pharmacol， 2024， 970：176492. doi:10.1016/j.ejphar.2024.176492 |
| 20 | CHEN J， CHEN C， ZHANG Z， et al. Exploring the key amino acid residues surrounding the active center of lactate dehydrogenase A for the development of ideal inhibitors［J］. Molecules， 2024， 29（9）：2029. doi:10.3390/molecules29092029 |
| 21 | CHEN M， CEN K， SONG Y， et al.NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma［J］. Cancer Lett， 2023， 567：216285. doi:10.1016/j.canlet.2023.216285 |
| 22 | ZHANG D X， ZHAO X H， GAO Y， et al. Inactivation of KDM6A promotes the progression of colorectal cancer by enhancing the glycolysis［J］. Eur J Med Res， 2024， 29： 310. doi:10.1186/s40001-024-01828-1 |
| 23 | WU D， WANG S， WANG F， et al. Lactate dehydrogenase A （LDHA）-mediated lactate generation promotes pulmonary vascular remodeling in pulmonary hypertension［J］. J Transl Med， 2024， 22： 738. doi:10.1186/s12967-024-05543-7 |
| 24 | HAILIWU R， ZENG H， ZHAN M， et al. Salvianolic acid A diminishes LDHA-driven aerobic glycolysis to restrain myofibroblasts activation and cardiac fibrosis via blocking Akt/GSK-3β/HIF-1α axis［J］. Phytother Re， 2023， 37（10）：4540-4556. doi:10.1002/ptr.7925 |
| 25 | SI Y， OU H L， JIN X， et al. G protein pathway suppressor 2 suppresses aerobic glycolysis through RACK1-mediated HIF-1αdegradation in breast cancer［J］. Free Radic Biol Med， 2024， 222： 478-492. doi:10.1016/j.freeradbiomed.2024.06.021 |
| 26 | WANG F， CHEN L， KONG D， et al. Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex［J］. Hepatology， 2024， 79（3）：606-623. doi:10.1097/hep.0000000000000569 |
/
| 〈 |
|
〉 |